The Society for Clinical Research Sites (SCRS) announced that StudyKIK has joined the organization as a Global Impact Partner (GIP). SCRS’ GIP Program provides an opportunity for sponsors, CROs, and solution providers to engage with SCRS and its members. Becoming a GIP demonstrates StudyKIK’s commitment to clinical research sites, their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions in the marketplace.
"StudyKIK has believed in SCRS and the vision Christine Pierre founded the organization on, which is to be the unified voice for all research sites, since its inception," said the company's president and co-founder, Matt Miller. "We started StudyKIK with the same vision by building tools to empower sites to succeed in patient recruitment. Becoming an SCRS Global Impact Partner strengthens our commitment to supporting research sites and connecting patients to clinical trials."
“By joining SCRS as a GIP, StudyKIK has demonstrated their commitment to a strong and unified site community,” said SCRS president Casey Orvin. “StudyKIK has had a consistent presence at SCRS’ Site Solutions Summits throughout the years, and we are looking forward to expanding our engagement with the company through the GIP program.”
For more information, visit www.MySCRS.org
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.